A randomized pilot trial of oral prednisone taper vs placebo following iv methylprednisolone for multiple sclerosis relapses: Effects on adrenal function and clinical efficacy.
Adrenal function
Relapses
Safety
Steroid taper
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
11
11
2020
revised:
26
01
2021
accepted:
22
02
2021
pubmed:
8
3
2021
medline:
15
5
2021
entrez:
7
3
2021
Statut:
ppublish
Résumé
We performed a pilot trial investigating the effect of a steroid taper on adrenal function and safety measures after acute MS relapses. Twenty-five patients were randomized to either prednisone taper (n=12) or placebo (n=13) after 3 days of intravenous methylprednisolone. No patient showed signs of adrenal insufficiency at any time by cortisol response to ACTH. This significantly increased between baseline and 6 months in both groups. Patients remained clinically and radiologically stable, but those under prednisone taper experienced more frequently mood disorders, hyperglycaemia and weight increase. If confirmed by sufficiently powered studies, these results would question the need of a steroid taper following short-term intravenous methylprednisolone.
Identifiants
pubmed: 33677411
pii: S2211-0348(21)00133-4
doi: 10.1016/j.msard.2021.102867
pii:
doi:
Substances chimiques
Prednisone
VB0R961HZT
Methylprednisolone
X4W7ZR7023
Types de publication
Letter
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
102867Informations de copyright
Copyright © 2021. Published by Elsevier B.V.